|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement?
|
| Published Date:
June 2009
Published By:
Decision Resources
Page Count:
37
Order Code:
R55-650
|
|
|
|
Introduction
For decades, the efficacy of hormone replacement therapy (HRT) for some of menopause’s most
troublesome symptoms eliminated any incentive to develop new approaches to treatment. However,
data questioning the safety of estrogen-containing therapies have galvanized researchers and drug
developers to begin investigating new mechanisms to treat menopausal symptoms that can capitalize
on the newly realized need for safer treatment options, although these agents will still be challenged
by the efficacy of HRTs.
Questions Answered in This Report
- Menopause is a natural process of aging that is accompanied b • y substantial hormonal changes.
What are the symptoms of menopause? What are the causes of these symptoms? What are the
current treatment options? What are the benefits and drawbacks of these treatments?
- Data from the Women’s Health Initiative suggest that estrogen therapy is not suitable for all women.
What are the risks associated with hormone therapy? Do emerging agents offer safer or more
efficacious treatment approaches?
- With the final wave of baby boomers reaching menopausal age, the menopause treatment patient
population is on the rise. What were the sales of menopausal symptom treatments in 2008? How
well will emerging agents address the remaining needs in this market? How will emerging
agents fit into the treatment algorithm in the future?
Scope
- Overview of menopause: Physiology and symptoms.
- Current treatments: Hormone replacement therapy, selective estrogen receptor
modulators, SSRIs/SNRIs, gabapentin.
- Emerging treatments: Wyeth’s Pristiq, Wyeth’s bazedoxifene/conjugated estrogens,
Depomed’s controlled-release gabapentin, Schering-Plough’s esmirtazapine.
- Outlook: 2008 market, challenges and opportunities, the potential of emerging agents, the
future of HRT.
- Women’s Health Series: This report is part of Spectrum’s Women’s Health Series, which
focuses on areas of unmet need and the best marketing strategies to ensure adoption of a
new agent into the market for women’s reproductive health—a sector that exceeded $23
billion in 2007.
|
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
